CoChat

Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5

Open access
Wang, Huabo, Chauhan, Jay, Hu, Angela, Pendleton, Kelsey, Yap, Jeremy L., Sabato, Philip E., Jones, Jace W., Perri, Mariarita, Yu, Jianshi, Cione, Erika, Kane, Maureen A., Fletcher, Steven, Prochownik, Edward V. · 2013 · Oncotarget
Cited by 57

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

// Huabo Wang 1 , Jay Chauhan 2 , Angela Hu 1 , Kelsey Pendleton 1 , Jeremy L. Yap 2 , Philip E. Sabato 3 , Jace W. Jones 2 , Mariarita Perri 4 , Jianshi Yu 2 , Erika Cione 4 , Maureen A. Kane 2,5 , Steven Fletcher 2,5 and Edward V. Prochownik 1,6,7 1 Section of Hematology/Oncology, Children’s Hospital of Pittsburgh of UPMC 2 Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA 3 PharmD Program, University of Maryland School of Pharmacy, Baltimore, MD, USA 4 Department of Pharmaco-Biology, University of Calabria, Rende (CS), Italy 5 University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA 6 Department of Microbiology and Molecular Genetics, The University of Pittsburgh School of Medicine 7 The University of Pittsburgh Cancer Institute, Pittsburgh, PA Correspondence: Edward V. Prochownik, email: // Steven Fletcher, email: // Keywords : 10058-F4, 10074-G5, intrinsically disordered proteins, JQ-1, BRD4 Received : May 31, 2013 Accepted : June 21, 2013 Published : June 22, 2013 Abstract The c-Myc (Myc) oncoprotein is a high-value therapeutic target given that it is deregulated in multiple types of cancer. However, potent small molecule inhibitors of Myc have been difficult to identify, particularly those whose mechanism relies on blocking the association between Myc and its obligate heterodimerization partner, Max. We have recently reported a structure-activity relationship study of one such small molecule, 10074-G5, and generated an analog, JY-3-094, with significantly improved ability to prevent or disrupt the association between recombinant Myc and Max proteins. However, JY-3094 penetrates cells poorly. Here, we show that esterification of a critical para -carboxylic acid function of JY-3-094 by various blocking groups significantly improves cellular uptake although it impairs the ability to disrupt Myc-Max association in vitro . These pro-drugs are highly concentrated within cells where JY-3-094 is then generated by the action of esterases. However, the pro-drugs are also variably susceptible to extracellular esterases, which can deplete extracellular reservoirs. Furthermore, while JY-3-094 is retained by cells for long periods of time, much of it is compartmentalized within the cytoplasm in a form that appears to be less available to interact with Myc. Our results suggest that persistently high extracellular levels of pro-drug, without excessive susceptibility to extracellular esterases, are critical to establishing and maintaining intracellular levels of JY-3-094 that are sufficient to provide for long-term inhibition of Myc-Max association. Analogs of JY-3-094 appear to represent promising small molecule Myc inhibitors that warrant further optimization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.1108

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Small-molecule inhibitors of protein–protein interactions: progressing towards the dream

    Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 2×

    “Another of our originally described Myc inhibitors, 10074-G5 (N-([1,1’-biphenyl]-2-yl)-7-nitrobenzo[c] [1,2,5]oxadiazol-4-amine) [21] binds to a more N-terminal region of Myc’s HLH domain ~35 residues removed from the 10058-F4 binding site [34].”
    Background
  • Reflecting on 25 years with MYC

    Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 1×

    “One prominent target of potentially high therapeutic value in cancer is the c-Myc (Myc) oncoprotein, a bHLHZIP transcription factor that is over-expressed and/ or deregulated by many different tumor types [12-14].”
    Background
  • Small-molecule perturbation of competing interactions between c-Myc and Max

    Follis, A. V., Hammoudeh, D. I., Daab, A. T., & Metallo, S. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.025 · Cited by 60 · cited 1×

    “The specificity of JY-3-094 and SF-3-103B for Myc-Max(S) heterodimers was also demonstrated by showing that neither compound appreciably affected DNA binding by Max(L) homodimers (IC50s >100 μM) whose free energy of association is actually less than that of Myc-Max heterodimers [38].”
    Background

Cited by

See all 57

Metadata

Authors
Wang, H., Chauhan, J., Hu, A., Pendleton, K., Yap, J. L., Sabato, P. E., Jones, J. W., Perri, M., Yu, J., Cione, E., Kane, M. A., Fletcher, S., & Prochownik, E. V.
Venue
Oncotarget
Published
2013-06-22
Volume
4
Issue
6
Pages
936-949
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1544358611
Cited by
57
References
3
FWCI
2.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.